A study on the immune response induced by a DNA vaccine encoding Mtb32C-HBHA antigen of Mycobacterium tuberculosis

Document Type: Original Article

Authors

1 Department of Microbiology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran

2 Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical science, Tehran, Iran

3 Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Objective(s): Tuberculosis (TB) has still remained a global health issue. One third of the world's population is infected with tuberculosis and the current BCG vaccine has low efficiency; hence, it is necessary to develop a new vaccine against TB. The aim of the current study was to evaluate the efficiency of a novel DNA vaccine encoding Mtb32C-HBHA antigen in inducing specific immune responses against Mycobacterium tuberculosis.
Materials and Methods: A DNA plasmid vaccine expressing Mtb32C-HBHA fusion protein was constructed and its ability in protein expression was examined by RT-PCR and Western blot methods. Female BALB/c mice were vaccinated with 100 μg of purified recombinant vector in an attempt to assess its immunogenicity and protective efficacy. Further, the cytokines, IFN-γ, IL-12, IL-4, IL-10, and TGF-β were assessed.
Results: The levels of all the studied cytokines were significantly increased (P<0.05) compared with the control group. IFN-γ production in the group receiving DNA vaccine plus BCG was increased compared with those receiving only DNA vaccine or BCG (P<0.001).
Conclusion: The immunogenicity of the new chimeric DNA vaccine was confirmed alone and in combination with BCG. Based on the results of the current study, the constructed DNA vaccine induced the expression of Mtb32C-HBHA fusion protein efficiently in vitro. Furthermore, high levels of the specific cytokines were induced in mice. By using this DNA vaccine as a booster after BCG, higher amounts of IFN-γ will be produced.

Keywords


1. Brewer TF. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin Infect Dis 2000; 3:S64-67.

2. Dara M, Dadu A, Kremer K, Zaleskis R, Kluge HH. Epidemiology of tuberculosis in WHO European Region and public health response. Eur Spine J 2013; 22:549-555.

3. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994; 271:698-702.

4. Delogu G, Fadda G. The quest for a new vaccine against tuberculosis. J Infect Dev Ctries 2009; 3:5-15.

5. Dietrich G, Viret JF, Hess J. Mycobacterium bovis BCG-based vaccines against tuberculosis: novel developments. Vaccine 2003; 21:667-670.

6. Parida SK, Kaufmann SH. Novel tuberculosis vaccines on the horizon. Curr Opin Immunol 2010; 22:374-384.

7. Ghanem A, Healey R, Adly FG. Current trends in separation of plasmid DNA vaccines: a review. Anal Chim Acta 2013; 760:1-15.

8. Pethe K, Aumercier M, Fort E, Gatot C, Locht C, Menozzi FD. Characterization of the heparin-binding site of the mycobacterial heparin-binding hemagglutinin adhesin. J Biol Chem 2000; 275:14273-14280.

9. Vidal Pessolani MC, Marques MA, Reddy VM, Locht C, Menozzi FD. Systemic dissemination in tuberculosis and leprosy: do mycobacterial adhesins play a role? Microbes Infect 2003; 5:677-684.

10. Krishnan N, Robertson BD, Thwaites G. The mechanisms and consequences of the extra-pulmonary dissemination of Mycobacterium tuberculosis. Tuberculosis (Edinb) 2010; 90:361-366.

11. Guerrero GG, Debrie AS, Locht C. Boosting with mycobacterial heparin-binding haemagglutinin enhances protection of Mycobacterium bovis BCG-vaccinated newborn mice against M. tuberculosis. Vaccine 2010; 28:4340-4347.

12. Locht C, Hougardy JM, Rouanet C, Place S, Mascart F. Heparin-binding hemagglutinin, from an extrapulmonary dissemination factor to a powerful diagnostic and protective antigen against tuberculosis. Tuberculosis (Edinb) 2006; 86:303-309.

13. Irwin SM, Izzo AA, Dow SW, Skeiky YA, Reed SG, Alderson MR, et al. Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein. Infect Immun 2005; 73:5809-5816.

14. Skeiky YA, Alderson MR, Ovendale PJ, Guderian JA, Brandt L, Dillon DC, et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 2004; 172:7618-7628.

15. Romano M, D'Souza S, Adnet PY, Laali R, Jurion F, Palfliet K, et al. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv. Vaccine 2006; 24:3353-3364.

16. Teimourpour R, Sadeghian A, Meshkat Z, Esmaelizad M, Sankian M, Jabbari AR. Construction of a DNA vaccine encoding Mtb32C and HBHA genes of mycobacterium tuberculosis. Jundishapur J Microbiol 2015; 8:e21556.

17. Teimourpour R, Zare H, Rajabnia R, Yahyapoor Y, Meshkat Z. Evaluation of the eukaryotic expression of mtb32C-hbha fusion gene of Mycobacterium tuberculosis in Hepatocarcinoma cell line. Iran J Microbiol 2016; 8:132-138.

18. Meshkat Z, Teimourpour A, Rashidian S, Arzanlou M, Teimourpour R. Immunogenicity of a DNA Vaccine Encoding Ag85a-Tb10. 4 antigens from mycobacterium tuberculosis. Iran J Immunol 2016; 13:289.

19. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.

20. Meshkat Z, Mirshahabi H, Meshkat M, Kheirandish M, Hassan ZM. Strong immune responses induced by a DNA vaccine containing HPV16 truncated E7 C-terminal linked to HSP70 gene. Iran J Immunol 2011; 8:65.

21. Ottenhoff TH, Kaufmann SH. Vaccines against tuberculosis: where are we and where do We need to go? PLoS Pathogens 2012; 8:e1002607.

22. Martin C. Tuberculosis vaccines: past, present and future. Curr Opin Pulm Med 2006; 12:186-191.

23. Feng CG PU, Demangel C, Spratt JM, Malin AS, Britton WJ. Priming by DNA immunization augments protective efficacy of Mycobacteriumbovis Bacille Calmette-Guerin against tuberculosis. Infect Immun 2001; 69:4174-4176.

24. Rouanet C, Lecher S, Locht C. Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis. Microbes Infect 2009; 11:995-1001.

25. Guerrero GG, Locht C. Recombinant HBHA boosting effect on BCG-induced immunity against Mycobacterium tuberculosis infection. Clin Dev Immunol 2011; 2011:730702.

26. Barker LF, Brennan MJ, Rosenstein PK, Sadoff JC. Tuberculosis vaccine research: the impact of immunology. Curr Opin Immunol 2009; 21:331-338.

27. Cavalcanti YV, Brelaz MC, Neves JK, Ferraz JC, Pereira VR.  Role of TNF-Alpha, IFN-Gamma, and IL-10 in the Development of Pulmonary Tuberculosis. Pulm Med 2012; 2012:10.

28. Redford P, Murray P, O’Garra A. The role of IL-10 in immune regulation during M. tuberculosis infection. Mucosal Immunol 2011; 4:261-270.

29. Jung YJ, Ryan L, LaCourse R, North RJ. Increased interleukin-10 expression is not responsible for failure of T helper 1 immunity to resolve airborne Mycobacterium tuberculosis infection in mice. Immunology 2003; 109:295-299.

30. Wyndham-Thomas C, Corbiere V, Dirix V, Smits K, Domont F, Libin M, et al. Key role of effector memory CD4+ T lymphocytes in a short-incubation heparin-binding hemagglutinin gamma interferon release assay for the detection of latent tuberculosis. Clin Vaccine Immunol 2014; 21:321-328.

31. Shafiani S DC, Ertelt JM, Moguche AO, Siddiqui I, Smigiel KS, et al. Pathogen-specific Treg cells expand early during mycobacterium tuberculosis infection but are later eliminated in response to Interleukin-12. J Exp Med 2013; 38:1261-1270.

32. Guerrero GG, Locht C. Recombinant HBHA boosting effect on BCG-induced immunity against Mycobacterium tuberculosis infection. Clin Dev Immunol 2011; 2011:730702.

33. Guerrero GG, Feunou FP, Locht C. The coiled-coil N-terminal domain of the heparin-binding haemagglutinin is required for the humoral and cellular immune responses in mice. Mol Immunol 2008;46:116-24.

34. Lebrun P, Raze D, Fritzinger B, Wieruszeski J-M, Biet F, Dose A, et al. Differential contribution of the repeats to heparin binding of HBHA, a major adhesin of Mycobacterium tuberculosis. PLoS One 2012; 7:e32421.